Addition of Venetoclax to Azacitidine Did Not Improve Survival in Acute Myeloid Leukemia and Was Not Well Tolerated: Real World Experience - PubMed
5 hours ago
- #acute myeloid leukemia
- #azacitidine
- #venetoclax
- Addition of Venetoclax to Azacitidine did not improve overall survival in AML patients.
- Real-world study showed AZA + Ven had lower tolerability and higher toxicity compared to AZA alone.
- Median overall survival was similar: 18 months for AZA vs. 14 months for AZA + Ven.
- Higher rates of severe neutropenia, thrombocytopenia, and anemia observed in AZA + Ven group.
- No significant difference in disease control between the two treatment groups.
- Study suggests need for larger, adjusted analyses due to imbalances in cytogenetic risk profiles.